News | March 26, 2013

600th Heart Attack Patient Recruited Into Phase III CicloMulsion CIRCUS Trial

March 26, 2013 — NeuroVive announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center clinical trial (CIRCUS trial) assessing CicloMulsion (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction.

The CIRCUS trial (does Cyclosporine ImpRove Clinical oUtcome in ST elevation myocardial infarction patients) is assessing CicloMulsion in a study of nearly 1,000 patients undergoing stenting following acute myocardial infarction to examine its ability to protect cardiac tissue and improve clinical outcome. CicloMulsion is a Cremophor-free formulation of the cyclophilin inhibitor, cyclosporine, under clinical development by NeuroVive for the treatment of cardiac reperfusion injury.

In 2008 a 58 patient study published in the New England Journal of Medicine (NEJM, 2008 Jul 31; 359 (5): 473-81) showed cyclosporine, when administered immediately prior to stenting, could reduce reperfusion injury by 40 percent in patients with myocardial infarction. The CIRCUS trial is designed to confirm these results in a much larger patient group.

The trial is a multicentre, randomized, placebo-controlled, double-blind, investigator-initiated study. Patients receive one single injection of CicloMulsion (or placebo) prior to reperfusion therapy by stenting. The incidence of the combined endpoint (mortality, hospitalization for heart failure, left ventricular (LV) remodeling) is then assessed one year after treatment to determine whether cyclosporine can improve ST elevation acute myocardial infarction (STEMI) patient clinical outcome. The study also includes a number of secondary outcome measures designed to provide a more detailed insight into CicloMulsion’s ability to reduce a patient’s level of cardiac injury following stenting.

The trial is being led by trial sponsor Professor Michel Ovize, M.D., Ph.D., of the University Hospital in Lyon (HCL), a leading expert in the field of cardiovascular medicine and it is conducted by a CRO unit within the hospital according to good clinical practice (GCP) guidelines. The study is enrolling patients at centers in France and additional sites in Belgium and Spain and is being funded by a number of European grant and public funding bodies. NeuroVive is supporting the study by providing active drug, placebo and drug logistics.

NeuroVive and HCL have recently agreed terms for the commercial use of the CIRCUS trial data, which it expects to report in early 2015. If successful, NeuroVive intends to use these data as part of a planned marketing authorization application with the EMA.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said, “The CIRCUS trial is very important for NeuroVive since if it confirms earlier trial results and demonstrates a significant improvement in patient outcome it will reinforce our view that CicloMulsion is an important new treatment for heart reperfusion injury following stenting. Therefore, the fact that the 600th patient has been recruited to the trial is greatly encouraging. The trial has been designed and conducted to the highest standards and we intend to use the data from this pivotal study for a Marketing Authorization Application in Europe for CicloMulsion.”

Professor Michel Ovize commented: “Reperfusion injury following stenting is affecting a growing global patient population suffering from cardiovascular disease. This group represents a huge medical need and one for which there are currently no approved pharmaceutical treatment options available. It is therefore critical to develop a drug to protect cardiac tissue following stenting. Cyclosporine has already shown the potential to reduce significantly the level of reperfusion injury and we are looking forward to confirming this important finding in the current CIRCUS study.”

For more information: www.neurovive.com


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now